Literature DB >> 19349163

Prognostic factors and outcomes for osteosarcoma: an international collaboration.

Emilios E Pakos1, Andreas D Nearchou, Robert J Grimer, Haris D Koumoullis, Adesegun Abudu, Jos A M Bramer, Lee M Jeys, Alessandro Franchi, Guido Scoccianti, Domenico Campanacci, Rodolfo Capanna, Jorge Aparicio, Marie-Dominique Tabone, Gerold Holzer, Fashid Abdolvahab, Philipp Funovics, Martin Dominkus, Inci Ilhan, Su G Berrak, Ana Patino-Garcia, Luis Sierrasesumaga, Mikel San-Julian, Moira Garraus, Antonio Sergio Petrilli, Reynaldo Jesus Garcia Filho, Carla Renata Pacheco Donato Macedo, Maria Teresa de Seixas Alves, Sven Seiwerth, Rajaram Nagarajan, Timothy P Cripe, John P A Ioannidis.   

Abstract

We aimed to evaluate the prognostic significance of traditional clinical predictors in osteosarcoma through an international collaboration of 10 teams of investigators (2680 patients) who participated. In multivariate models the mortality risk increased with older age, presence of metastatic disease at diagnosis, development of local recurrence when the patient was first seen, use of amputation instead of limb salvage/wide resection, employment of unusual treatments, use of chemotherapeutic regimens other than anthracycline and platinum and use of methotrexate. It was also influenced by the site of the tumour. The risk of metastasis increased when metastatic disease was present at the time the patient was first seen and also increased with use of amputation or unusual treatment combinations or chemotherapy regimens not including anthracycline and platinum. Local recurrence risk was higher in older patients, in those who had local recurrence when first seen and when no anthracycline and platinum were used in chemotherapy. Results were similar when limited to patients seen after 1990 and treated with surgery plus combination chemotherapy. This large-scale international collaboration identifies strong predictors of major clinical outcomes in osteosarcoma.

Entities:  

Mesh:

Year:  2009        PMID: 19349163     DOI: 10.1016/j.ejca.2009.03.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  59 in total

1.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

2.  Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis.

Authors:  Xi Wang; Yujie Ning; Lei Yang; Huan Liu; Cuiyan Wu; Sen Wang; Xiong Guo
Journal:  Clin Exp Med       Date:  2016-04-22       Impact factor: 3.984

3.  The relation of tumour necrosis and survival in patients with osteosarcoma.

Authors:  Xin Li; Adedayo O Ashana; Vincent M Moretti; Richard D Lackman
Journal:  Int Orthop       Date:  2011-02-26       Impact factor: 3.075

4.  Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide.

Authors:  Lingzhi Zhong; Yang Wang; Wenxue Li; Junlian Gu; Xiuying Li; Xiaotong Wang; Zhen Yue; Yan Mu; Jinping Bai; Ronggui Li; Haiying Zhang
Journal:  Mol Cell Biochem       Date:  2014-03-28       Impact factor: 3.396

5.  Extracorporeally irradiated autografts for the treatment of bone tumours: tips and tricks.

Authors:  Bart Poffyn; Gwen Sys; Alexander Mulliez; Georges Van Maele; Luc Van Hoorebeke; Ramses Forsyth; Dirk Uyttendaele
Journal:  Int Orthop       Date:  2010-07-22       Impact factor: 3.075

6.  Adipose tissue and muscle attenuation as novel biomarkers predicting mortality in patients with extremity sarcomas.

Authors:  Joyce Veld; Josephina A Vossen; Karen De Amorim Bernstein; Elkan F Halpern; Martin Torriani; Miriam A Bredella
Journal:  Eur Radiol       Date:  2016-03-09       Impact factor: 5.315

7.  Depletion of ALX1 causes inhibition of migration and induction of apoptosis in human osteosarcoma.

Authors:  Mingfu Yang; Yong Pan; Yue Zhou
Journal:  Tumour Biol       Date:  2015-03-04

8.  Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.

Authors:  Roelof Koster; Orestis A Panagiotou; William A Wheeler; Eric Karlins; Julie M Gastier-Foster; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Adrienne M Flanagan; Roberto Tirabosco; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Ana Patiño-Garcia; Fernando Lecanda; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; David M Thomas; Mandy L Ballinger; Richard Gorlick; Donald A Barkauskas; Logan G Spector; Margaret Tucker; D Hicks Belynda; Meredith Yeager; Robert N Hoover; Sholom Wacholder; Stephen J Chanock; Sharon A Savage; Lisa Mirabello
Journal:  Int J Cancer       Date:  2017-12-23       Impact factor: 7.396

9.  Telangiectatic osteosarcoma: a review of 87 cases.

Authors:  Andrea Angelini; Andreas F Mavrogenis; Giulia Trovarelli; Stefano Ferrari; Piero Picci; Pietro Ruggieri
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-28       Impact factor: 4.553

10.  Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy.

Authors:  Rosalvo Zósimo Bispo Júnior; Olavo Pires de Camargo
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.